217 related articles for article (PubMed ID: 26970503)
1. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
[TBL] [Abstract][Full Text] [Related]
2. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids.
Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916
[TBL] [Abstract][Full Text] [Related]
4. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
Hooper C; Calvert J
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081
[TBL] [Abstract][Full Text] [Related]
5. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.
Zeng Z; Yang D; Huang X; Xiao Z
Int J Chron Obstruct Pulmon Dis; 2017; 12():2277-2283. PubMed ID: 28814855
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life.
Alibašić E; Skopljak A; Čengić A; Krstović G; Trifunović N; Čatić T; Kapo B; Mehić M; Hadžimuratović A
Med Glas (Zenica); 2017 Aug; 14(2):182-188. PubMed ID: 28786969
[TBL] [Abstract][Full Text] [Related]
7. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
8. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.
Tatsumi K; Fukuchi Y;
J Am Geriatr Soc; 2007 Nov; 55(11):1884-6. PubMed ID: 17979906
[No Abstract] [Full Text] [Related]
9. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
10. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys).
Carpagnano GE; Resta O; Foschino-Barbaro MP; Spanevello A; Stefano A; Di Gioia G; Serviddio G; Gramiccioni E
Eur J Pharmacol; 2004 Nov; 505(1-3):169-75. PubMed ID: 15556150
[TBL] [Abstract][Full Text] [Related]
11. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
12. Carbocisteine for acute exacerbations of COPD.
Waller P; Suissa S
Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
[No Abstract] [Full Text] [Related]
13. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
14. Carbocisteine for acute exacerbations of COPD.
Mohapatra PR; Aggarwal D
Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
[No Abstract] [Full Text] [Related]
15. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells.
Yamaya M; Nishimura H; Shinya K; Hatachi Y; Sasaki T; Yasuda H; Yoshida M; Asada M; Fujino N; Suzuki T; Deng X; Kubo H; Nagatomi R
Am J Physiol Lung Cell Mol Physiol; 2010 Aug; 299(2):L160-8. PubMed ID: 20543005
[TBL] [Abstract][Full Text] [Related]
17. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
18. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study.
Kuyucu T; Güçlü SZ; Saylan B; Demir C; Senol T; Güner S; Koyuncu E; Ozen F; Oztürk S; Cangül Z; Ağanoğlu S; Ozkaya S; Ocak SC; Akkurt H; Intepe YS; Bayrak MG; Güler T; Bekçi TT; Soyyiğit S; Seyfettin S; Kula O; Akbay MO; Büyükgöze B; Asal G; Başlilar S; Oztürk O;
Tuberk Toraks; 2011; 59(4):328-39. PubMed ID: 22233302
[TBL] [Abstract][Full Text] [Related]
19. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
Bateman ED; Feldman C; O'Brien J; Plit M; Joubert JR;
S Afr Med J; 2004 Jul; 94(7 Pt 2):559-75. PubMed ID: 15283307
[TBL] [Abstract][Full Text] [Related]
20. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
